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Review
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The bio-nano-interface in predicting nanoparticle
fate and behaviour in living organisms: towards
grouping and categorising nanomaterials and
ensuring nanosafety by design
Abstract: In biological media, nanoparticles acquire a coating
of biomolecules (proteins, lipids, polysaccharides) from their
surroundings, which reduces their surface energy and confers
a biological identity to the particles. This adsorbed layer is the
interface between the nanomaterial and living systems and
therefore plays a significant role in determining the fate and
behaviour of the nanoparticles. This review summarises the
state of the art in terms of understanding the bio-nano interface and provides direction for potential future research and
recommendations for future priorities and strategies to
support the safe implementation of nanotechnologies. The
central premise is that nanomaterials must be studied as
biological entities under the appropriate exposure conditions and that this should be implemented in study design
and reporting for nanosafety assessment. The implications
of the bio-nano interface for nanomaterials fate and behaviour are described in light of four interlinked perspectives:
the Coating concept; the Translocation concept; the Signalling concept, and the Kinetics concept. A key conclusion
is that nanoparticles cannot be viewed as non-interacting
species, but rather must be thought of, and studied as, biological entities, where their interaction with the environment
is mediated by the proteins and other biomolecules that
adsorb to them, and the key parameter to characterise then
becomes the nature, composition and evolution of the bionano interface.
Keywords: biological identity; biomolecule corona; bionano interface; nanomedicine; nanoparticle; nanosafety;
synthetic identity.
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The bio-nano interface – providing a
biological identity to nanomaterials
The role of nanoparticle interaction with biological molecules as the key to nanomedicine and nanotoxicity has
emerged recently [1], with the development of the idea of
the nanoparticle-protein or biomolecule corona [2]. This
is the dynamic layer of proteins and other biomolecules
that adsorbs to nanoparticle surfaces immediately upon
contact with living systems and is what organisms or
cells “see” and interact with [3]. Unlike bulk biomaterials, however, the fact that nanoparticles are sufficiently
small that they can reach sub-cellular locations results in
significant new potential impacts, specifically in terms of
their interactions with biomolecules and biomembranes.
The consequences of this for nanoparticle uptake and biodistribution and nanoparticle-induced signalling impacts
need to be considered. A recent review of nanoparticles
interacting with biological systems suggests that nanoparticles are mobile solids, combining the properties of
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solids (for example, fluorescence in the case of quantum
dots where the constituent components are non-fluorescent) with the ability to thermally diffuse (a property of
molecules) [4]. Their large surface area allows them to act
as a scaffold for protein and biomolecule binding, leading
nanoparticles to acquire a biological identity, or a bionano interface. The nanoparticle protein or biomolecule
corona hypothesis suggests that the biomolecules (proteins, lipids, nucleic acids etc.) that reside on the particle
determine its biological identity and subsequent impacts
[3]. The view is thus emerging that one should correlate
the properties of the nanoparticle corona or its bio-nano
interface to the biological activity/responses rather than
simply the bare nanomaterial properties [5].
It is clear that the biological behaviour and consequences of nanoparticles are largely dictated by how they
interface to biology. The idea of airborne particulates
becoming coated with lung surfactant lipid following
inhalation was postulated in 1990 [6]. Proteins and lipids
in lung lining liquid at the air-liquid (alveolar fluid, hypophase) interface – the first biostructure an inhaled nanoparticle encounters when deposited in the alveoli – were
later observed to coat urban nanoparticles in a corona and
cause nanoparticle aggregation [7–9].
This lung-surfactant corona was later proposed as
an important protective mechanism mediating the health
impacts associated with breathing in airborne particles
and nanoparticles in urban air [10]. Despite early evidence
of particle coronas in the lung identified using newly developed atomic and molecular scale techniques [11], the biological interface remains the least understood aspect about
nanoparticles, and classification systems to characterise
the outermost layers of the bio-nano interface, i.e., those
biological signatures that are available to engage endogenous cellular machinery, are absent. By far the most studied
component of the corona is the protein composition [7, 12],

but lipids, sugars and other species likely also play a role
[13–15]. Thus, despite the importance of the bio-nano interface, and the fact that it potentially holds the key to both
safe implementation of nanotechnologies and nanomedicine, efforts to characterize it are surprisingly scarce [16].
While the focus of this review is on biomolecules such as
proteins and lipids, the ideas are equally applicable to nanoparticles dispersed in environmental milieu, where decaying plant and animal matter results in so-called natural
organic matter, typically composed of polysaccharides,
interact with nanoparticles affecting their stability, dispersability and environmental fate and behaviour [17, 18, 19].
Significant advances have been made in the last 5
years, both in understanding of the importance of the bionano interface and in terms of methods and approaches
to study it. Evidence for this wide scale acceptance of
the concept of the nanoparticle biomolecule corona and
the importance of the bio-nano interface comes from the
fact that the OECD Sponsorship Programme has included
characterisation of nanoparticles in biofluids as part of
their list of endpoints at the end of 2010 [20].
Before getting into the details of the state of the art and
recommendations for moving beyond this it is important
to note that interactions between nanoparticles and biomolecules, and the formation of the bio-nano interface,
has consequences for both the nanoparticle surface itself,
and potentially also for the proteins and other biomolecules contained in the biomolecule corona. A summary
of some of these effects, and reviews or key publications
relating to these effects, are given in Table 1.
The emerging discipline of nanotoxicology may be
viewed essentially as the study of the undesirable interference between man-made nanomaterials and cellular nanostructures or nanomachines [35]. In parallel,
the considerable allure of engineered nanoparticles for
clinical applications is due to the fact that these artificial

Table 1 Nanoparticle-biomolecule interactions and the formation of the bio-nano interface has consequences for both the adsorbed biomolecules and for the nanoparticle surface and dispersion.
Effect of adsorption on Biomolecules:

Effect of interaction on Nanoparticles:

– c onformation changes → blocked or enhanced presentation
of active sites and subsequent functional changes [21, 22]
– altered propensity for protein-protein interactions (e.g.,
fibrillation) [26]

– c onferring a biological identity – altered interaction/uptake and
biodistribution [23–25]
– altered surface characteristics and thereby stability and dispersability
[8, 27] and potentially also dissolution potential (as per environmental
macromolecules such as humic acids) although limited literature [28]
– reduced surface energy/reactivity [30] (possibly only temporarily)

– oxidative effects – lesions, post-translational effects,
etc. [29].
– depletion of medium components which can result in
indirect toxicity effects [8, 10, 31]
– altered kinetics (distribution, half-life, degradation, etc.)
[21, 33]

– m
 asking targeting or other bio-functional elements? (possibly only
temporarily) [32]
– Altered bioactivity [23, 34]
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entities are designed to interact with biological systems at
the nano-scale. Moreover, understanding and controlling
the bio-nano-interface is equally important both from a
nanomedicine and nanotoxicology point of view. In fact,
a recent study reported that the adsorption of serum proteins obscures targeting ligands grafted to nanoparticles
(in this case: transferrin) thereby preventing targeted
uptake, as shown schematically in Figure 1 [32]. This demonstrates the importance of biomolecular interactions
in determining nanoparticle uptake, uptake mechanism
and fate and behavior in living systems. It is important
to note that the size ratio between nanoparticle and proteins plays a vital role in determining nanomaterial-protein (macromolecule) interactions, and indeed for many
types of inherently small nanomaterials (e.g., Quantum

TfR
SiO2-PEG8-TF

Different serum proteins

Figure 1 The biomolecule corona masks targeting ligands: Transferrin-functionalised nanoparticles lose their targeting capabilities
when a biomolecule corona adsorbs on the surface. Schematic
representation of loss of TfR targeting for Tf-conjugated nanoparticles in the presence of FBS proteins (endogenous Tf, where present,
could also compete for TfR). Reproduced from [32]. Note that the
particles in this schematic are intended to represent ~50 nm particles, but that the nanoparticles and proteins are not drawn to scale.
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dots which are typically < 5 nm) the nanomaterials may
be smaller than the proteins, as discussed in Klein et al.
[36] and demonstrated by Deng et al. in their study of the
role of gold nanoparticle size on binding to fibrinogen,
whereby small changes in nanomaterial size (from 8 nm
to 10–12 nm to 15 nm) resulted in significant differences
in how the protein and nanomaterials interacted [37]. The
schematic figures in this manuscript (taken from the literature) are not drawn to scale, but are intended only to
illustrate the principles and concepts being described.
The fact that many endogenous transport and other
processes utilise biomolecule clusters in the nanoscale,
such as the lipoprotein complexes, e.g., chylomicrons
( > 100 nm) and High Density Lipoproteins (8–10 nm), and
ribosomes (DNA and protein clusters; 25–30 nm), suggests
that in many cases nanoparticles may simply be recognised as scaffolds onto which biomolecules can adsorb
as part of the normal functioning of the biomolecules
[38]. Indeed, most spherical nanoparticles studied to date
have been shown to bind lipoproteins, often with a size
and surface curvature influence, in addition to a compositional influence, such as from surface charge [21].
Building on this background and the current state of
the art, we suggest some potential future research directions and make recommendations for future priorities
and strategies to ensure that the importance of the bionano interface is recognised. Central to this is the fact
that nanomaterials must be studied as biological entities under the appropriate exposure conditions, and that
this approach must be implemented in study design and
reporting for nanosafety assessment. The implications of
the bio-nano interface for nanomaterials fate and behaviour are described from four primary perspectives:
–– the Coating concept,
–– the Translocation concept,
–– the Signalling concept,
–– the Kinetics concept.
In this paper we considered that the principles outlined
hold for all nanoparticles types, and thus the examples
cited from the literature may refer to metallic, metal oxide,
carbon based, polymer coated or polymeric nanoparticles, quantum dots etc. Clearly surface chemistry matters,
as does size and shape, in terms of the finer details of how
each different particle type behaves, but we believe that
the principles hold generally and indeed that these could
form the basis of a future classification strategy that is
independent of nanomaterial composition or structure.
The four primary perspectives presented here align well
with, and indeed expand upon, the three “principles of
nanotoxicology” described by Krug and Wick, namely the
Brought to you by | Dublin Institute of Technology
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Transport Principle, the Surface Principle and the Material Principle [39] and focus on the role of biomolecules in
providing a crucial interface between nanoparticles themselves (which are seen more as scaffolds for protein/biomolecule binding) and biological systems. Indeed, a key
conclusion is that nanoparticles must be thought of, and
studied as, biological entities, where their interaction with
the environment is mediated by the proteins and other
biomolecules that adsorb to them, and the key parameter
to characterise then becomes the nature, composition and
evolution of the bio-nano interface.

The coating concept: Interactions of
nanoparticles with proteins, lipids,
polysaccharides, DNA/RNA, natural
organic matter, etc.
Scientists increasingly recognise that nanoparticles immediately absorb proteins and/or other biomolecules from
their surroundings to lower their surface free energy [40]
with important consequences for nanoparticle stability in
dispersion [41], and interaction with biological systems.
Protein binding to nanoparticles changes both the hydrophobicity of the outermost surface (the bio-nano interface)
and the effective surface charge, with even very positively
charged nanoparticles typically presenting a neutral to
slightly negative zeta potential in plasma or cell culture
medium containing foetal calf serum. Note that for ecotoxicological studies, natural organic matter plays much
the same role as proteins for in vitro and in vivo toxicology
studies, modulating the nanoparticle surface (free energy)
and thus the dispersibility of nanomaterials [18] and interaction with biological systems. As a consequence, nanoparticles dispersed in biofluids containing proteins, lipids,
polysaccharides, etc. can have a very different dispersion
profile than the same nanoparticles dispersed in reference buffers, which can lead to very different effective or
available doses of nanoparticles for interaction with living
systems [3, 5]. The understanding that nanoparticles in a
biological medium are remarkably strongly associated to
a biomolecular layer (rich in proteins in vivo) drawn from
their environment shifts the focus of studies and discussions away from the bare material identity to a new, more
nuanced, conception in which particle size, shape and
corona expression (collectively the bio-nano interface) are
more likely to be the defining features of nanomaterial biological identity and consequently fate and behaviour. Thus,
in addition to describing the physico-chemical properties

(the so-called “Synthetic identity”), a “biological” property
should be added to describe the nanoparticles as they exist
in the relevant exposure context [42], as shown in Figure 2.
The composition of the biomolecule corona, and the
subsequent evolution as a particle moves from one biological environment to another [44], available dose and consequent biological interactions of the coated nanoparticles,
have been found to depend on the specific details of the
biofluid in which the nanoparticles are dispersed, which
may account for much of the contradictory reports present
in the literature for nominally identical materials to date
[5]. Thus, the same (batch of) nanoparticles dispersed in
different cell culture media (e.g., DMEM or RPMI) containing identical concentrations of Foetal Bovine Serum
(FBS) from the same batch have been shown to result in
quite different coronas, both in terms of their thickness
and dynamics [25]. The authors of that study observed
that DMEM elicits the formation of a large time-dependent
protein corona, while RPMI shows different dynamics with
reduced protein coating. These different coronas, which
resulted from the different ionic strengths and salt compositions of the media, had implications for uptake and
impact, with the protein-nanoparticle complexes formed
in RPMI being more abundantly internalized in cells as
compared to protein-nanoparticle complexes formed in
DMEM, consequently exerting overall stronger cytotoxic
effects [25]. These results suggest that cell culture medium
composition and ionic strength can alter adsorption of
proteins onto the nanoparticle surface, which can impact
on the particle agglomeration and potentially alter the

Nanomaterials classification and grouping

Synthetic identity

Biological identity
(context dependent)

Bio-nano interactions
Coating
translocation
signalling
kinetics

Measurement principles
for NM identification in
different environments and
matrices

Identification of metrics
relevant for safety
assessment

Figure 2 The importance of understanding the inter-relationship
between the synthetic and biological identities of nanomaterials for
hazard assessment, identification and classification of nanomaterials). Figure re-drawn from the NanoSafety in Europe 2015–2025
report [43].
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available dose of nanoparticles under the different exposure conditions. However, in the absence of characterisation of the nanoparticles in the two different media, it is
not possible to make any interpretation of the data on the
basis of whether the different protein coronas result in
different available doses, which could potentially explain
the different observed impacts [5]. In other studies, the
surface chemistry profiles of airborne particle samples
collected in different continents, and exposed to the lung
lining liquid of different subjects, showed surprising consistency and resulted in similar aggregation effects [9].
Similar data resulted from comparison of corona composition and cellular uptake of nanoparticles dispersed in
cell culture media containing 10% foetal calf serum that
had either been heat inactivated (to remove the complement proteins) or not heat inactivated [24]. Here also, the
particles with the lower protein content in their coronas
entered cells more effectively than those with higher
protein content in their coronas [24, 45]. Related work has
shown that the composition of the nanoparticle biomolecule corona can depend on the ratio of nanoparticle surface
area to available proteins, with the consequence that nanoparticle coronas prepared under conditions typical for in
vitro testing (i.e., 3%–10% serum proteins in medium) may
not be representative of the corona that would form under
in vivo conditions (typically 55%–80% proteins) [30].
A study of the interaction of nanoparticles with surfactant protein A (SP-A), a significant protein component
of alveolar lining fluid, found different particle-protein
interactions for each of eight different nanoparticles [46].
Interestingly, three variants of the same material (cerium
dioxide nanoparticles) revealed different adsorption patterns despite the materials being nominally identical and
indistinguishable in electron microscopy images [46].
This suggests that the biomolecule corona composition, or
the details of the bio-nano interface, could be a very sensitive tool to distinguish subtle material differences and
to predict biological impacts, once correlations between
adsorbed biomolecules and signalling or other effects are
confirmed. In contrast, surfactant protein D (SP-D) alters
cellular uptake in a different way [47].
Multiple studies have assessed the effect of nanoparticle composition [38, 48, 49], size [49, 50], surface coating
[51, 52], shape and other physico-chemical parameters on
the nature and composition of the protein corona. Recent
reviews have attempted to summarise the many factors
that have been found to influence protein–nanoparticle
interactions [53, 54], and have described these factors as
falling into three categories: protein (or macromolecule)related (molecular weight, isoelectric point (pI), and
conformational flexibility), NM-related (species, size,
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shape, charge, roughness, hydrophobicity, crystallization,
defects, and functionalization), and medium-related (pH
and ion strength) [54].
In the case of nanoparticles dispersed in the environment, interaction with environmental organic matter and
biological molecules has been shown to determine their
subsequent effects and fate in a similar manner. Some
studies have shown that nanoparticles can adsorb natural
organic matter to form complexes and, as a consequence of
such coating, they may become negatively charged, altering their fate and transport in the aqueous environment
[55, 56]. Humic acids are a major part of the natural organic
matter contained in soil and fresh water. Their structure,
which consists of a skeleton of alkyl/aromatic units crosslinked mainly by oxygen and nitrogen groups with the major
functional groups being carboxylic acid, phenolic and alcoholic hydroxyls, ketone and quinine groups, allows them to
behave as surfactants, with the ability to bind both hydrophobic and hydrophilic materials [57]. As a consequence of
this behavior, nanoparticle-humic acids interactions should
be a factor of relevance in the study of the life cycle of nanomaterials, and likely natural organic matter plays a similar
role in the environment that proteins do for human health.
We thus propose that it is vital that nanomaterials be
considered as biological entities, and studied as such.1 Key
steps in the short to medium term include understanding
and eventually predicting which chemical, geometrical
and physico-chemical parameters of nanomaterials lead
them to preferentially adsorb which proteins, and connecting the absorbed proteins with observed impacts,
such as uptake, localization and signaling. For example,
the role of opsonins and dysopsonins is well understood
in terms of phagocytic recognition [58, 59]. However,
much work is required to tease out the signaling pathways
influenced by biomolecules contained at the bio-nano
interface, whether these be functioning normally or experiencing altered functionality as a result of conformation
changes induced by binding to the surface.

The translocation concept:
interactions of nanomaterials with
cells, tissues, barriers, etc.
The human body has four portals of entry for nanoparticles: three natural portals, the lung, the digestive tract and
1 http://www.skep-network.eu/Libraries/Network_documents/
SKEP_Nanomaterials_in_REACH_Report.sflb.ashx.
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the intact skin, and one artificial portal, the veins, into
which nanoparticles can be injected. It has been shown
that nanoparticle translocation into capillaries leads to
their translocation into other organs [60–65], and evidence
is emerging that the route of entry, and the biomolecules
that form the initial corona at the site of entry (e.g., plasma
proteins following injections versus lung surfactant proteins following inhalation), play a distinct role in determining the organ biodistribution of nanoparticles [66]. For
example, accumulation of TiO2 nanoparticles in the brain
was 100-fold higher for particles entering via lung than
for those injected directly into the bloodstream (Personnal Communication W.G. Kreyling). Further evidence for
the importance of the initial bio-nano interface, which is
determined by the route of exposure, comes from a study
of the interaction of magnetite nanoparticles (110–180 nm
in diameter), coated with different polymers (starch, carboxymethyldextran, chitosan, poly-maleic-oleic acid,
phosphatidylcholine), with alveolar macrophages [67].
Cellular binding and uptake of nanoparticles by alveolar
macrophages was increased for nanoparticles treated with
SP-A, whereas albumin, the prevailing protein in plasma,
led to a significant decrease. This study provides evidence
that, after inhalation of nanoparticles, a different protein
coating and thus different biological behavior may result
compared to direct administration to the bloodstream [67].
A direct effect of biomolecule corona composition
on nanoparticle biodistribution has been shown in an
elegant study using radiolabelled gold nanoparticles of
five different sizes (1.4, 5, 18, 80, and 200 nm) and 2.8 nm
gold nanoparticles with opposite surface charges following intravenous injection into rats [68]. Results indicated that both size and surface charge of nanoparticles
strongly determined the biodistribution, with different
charge particularly leading to significantly different
accumulations in several organs. The authors concluded
that the alterations of accumulation in the various organs
and tissues, depending on nanoparticle size and surface
charge, were mediated by dynamic protein binding and
exchange [68].
When interacting with cells, nanomaterials come
into close contact with the cell membrane, a dynamic
structure that segregates the chemically distinct intracellular milieu (the cytoplasm) from the extracellular
environment by coordinating the entry and exit of small
and large molecules. Macromolecules are carried into
the cells in membrane bound vesicles derived from the
invagination and pinching-off of pieces of the plasma
membrane to form endocytic vesicles. This process,
termed endocytosis, has different features depending on
the size and type of the molecule/structure internalized:

receptor-independent endocytosis (fluid-based endocytosis and macropinocytosis), and several types of
receptor-dependent endocytosis (clathrin-dependent,
lipid-raft-independent, lipid raft-dependent/caveolaeindependent, and caveloae-dependent). These endogenous processes are exploited by bacteria and viruses
for invading cells, and it is likely that also nanoparticles
may enter cells through them, although there are quite
conflicting reports as to the exact mechanism(s) mediating cell entry by different nanoparticles [69–72]. Very
likely this is a result of different bio-nano interfaces.
A recent review of cellular uptake of nanoparticles
describes work revealing active endocytosis mechanisms
and pathways involved in their cellular uptake, and
summarises the current state of knowledge: Interested
readers are referred here for more details [73]. All endocytic pathways have a feature in common, in that the
particle, which entered the cell, is finally located in an
intracellular vesicle, typically the lysosome, as the final
sub-cellular destination [74–76]. However, there are
studies, which reported the intracellular localization of
nanoparticles that were not membrane bound, suggesting alternative pathways for particles to enter, or that the
nanoparticles can escape the endosomes, as a result of
endosomolysis [77–80]. This alternative way of nanoparticle penetration into cells, i.e., through the cell membrane, has been called “adhesive interaction” (by van
der Waals and other forces) and has been suggested as
an alternative mechanism of passive entry [81]. Another
recent publication offers convincing evidence for a
passive mechanism whereby nanoparticles enter cells
by membrane penetration on an experimental and calculation basis [80]. The fact that nanoparticles are found
free in the cytoplasm following uptake via the adhesive
mechanism is noteworthy, since free nanoparticles in the
cytoplasm may cause cellular effects different from those
contained in vesicles (which entered the cell probably
by an endocytic mechanism). Moreover, the intracellular trafficking may be different and also interaction with
intracellular structures like the cytoskeleton, the organelles and the nucleus may be via direct contact for free
nanoparticles. These aspects may all contribute to the
different reactions of the cell to different nanoparticles,
and are worthy of further investigation.
Very significant modulatory effects of proteins and
the bio-nano interface have been observed in terms of
nanoparticle uptake by human macrophages, by undifferentiated and by PMA-differentiated monocytic THP-1 cells
of 50 nm and 100 nm fluorescently-labelled carboxyl- or
amine- modified polystyrene nanoparticles from medium
with and without (serum free medium) serum proteins
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[59]. The amount of internalized nanoparticles, the uptake
kinetics, and its mechanism were critically dependent on
particle opsonization by serum proteins, with nanoparticles being rapidly internalized by cells in serum-free (SF)
medium until they reached saturation kinetics, whereas
in 10% human AB serum-enriched (SE) medium the nanoparticle uptake rate was drastically reduced as the uptake
was via receptor-mediated processes [59]. Thus, in terms
of understanding nanoparticle uptake and biokinetics,
the bare material surface is clearly the wrong parameter
to use, and indeed uptake studies in the absence of an
appropriate biomolecule environment report on uptake as
a result of membrane damage in an artefactual situation
[34], rather than on nanoparticle uptake utilising endogenous pathways.
However, one important question that remains to
be answered is whether the protein and biomolecule
layer on the nanoparticle surface mediates the binding
to cells through one or more specific active mechanisms
or via non-specific interactions, whereby the biomolecules behave as a simple coating which reduces the
surface energy of the nanoparticles. There are considerable differences in interpretation in the literature to date
regarding uptake mechanisms, and approaches such as
poisoning the endocytic receptors using pharmacological inhibitors or silencing of selected proteins involved
in specific endocytic pathways (e.g., clathrin or caveolin)
suggest that the same nanoparticle might exploit different uptake mechanisms to enter different cell types or
indeed the same cell type under different conditions [82].
Similar results have been reported for nanoparticles engineered for targeting the folate receptor: folate receptorspecific siRNA was used to reduce folate receptor levels
and uptake of heparin-folate-paclitaxel nanoparticles by
target cells, but silencing only reduced uptake to half of
its value in the control cells, suggesting multiple pathways of uptake [72]. A recent study of differently surface
modified 100 nm polystyrene nanoparticles indicated
that different specific protein coronas did not result in differential association of the particles to endothelial cells,
suggesting that binding and cellular uptake by these cells
may not be triggered by interaction of the protein corona
with specific receptors [83]. The authors suggested that
an assessment of the adsorptive capacity of nanoparticles
could be useful in order to predict the magnitude of nanoparticle cellular interactions. Much of the success to date
in terms of nanoparticles for drug delivery has been the
result of fortuitous absorption of endogenous transporter
proteins, such as Apolipoprotein E, to nanoparticles, or
deliberate functionalisation of nanoparticles with these
proteins [84, 85].
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Once it is recognised that the biointerface is the key
parameter to understand in terms of determining mechanisms of uptake of nanomaterials, a key question becomes
how researchers can target nanoparticles to best utilise
these pathways, and simultaneously avoid non-specific
protein interactions, by designing the bio-nano interface. Several recent reviews highlight the various endogenous uptake pathways available to nanomaterials, and
examples of therapeutic strategies that could potentially
utilise these pathways [86, 87]. Indeed, there has been
considerable effort devoted to development of targeting
nanoparticles, such as conjugation of 100-nm polystyrene nanoparticles with glycocalicin, which significantly
increased the particle adhesion on P-selectin-coated surfaces and cellular uptake of nanoparticles by activated
endothelial cells under physiological flow conditions [88],
or functionalisation of cerium oxide nanoparticles with
transferrin (Tf), to increase preferential uptake by transferrin receptor (TfR) over-expressing human lung cancer
cells (A549) and normal embryo lung cells (WI-38) [89]. A
key finding from this work is that the strength of interaction between the nanoparticles and the targeting protein
(Tf in this case) can be tuned by modifying the surface
charge of the nanoparticles, and that binding energy
values could be correlated with cellular uptake (as shown
schematically in Figure 3) [89], in a first step towards
quantitative structure-activity relationships (QSARs).
The task of modeling, and ultimately predicting,
the distribution and fate of nanoparticles represents an
interesting, and quite new challenge [76]. A flux-based
approach, based on live cell imaging of fluorescent
nanoparticle uptake and transport in a time resolved
manner has shown that the nanoparticles rapidly localize to endosomes (1 h) and later to lysosomes (by 4 h),
with no evidence of nanoparticles exiting from lysosomes once they have arrived there [76]. The observed
decrease in fluorescence over time was shown to correlate with cell division, and with the nanoparticle load
being split evenly between the two daughter cells. While
vesicle recycling is a normal part of cell homeostasis, no
recycling of fluorescent nanoparticles from vesicles was
observed in the above study [76]. Indeed, another study
has shown that relatively few 40 or 100 nm carboxylicmodified polystyrene nanoparticles are able to access
endocytic recycling pathways, as judged by the lack of
significant co-localization with Rab11, a key protein associated with recycling vesicles [90]. There is no evidence
that corona-driven export processes exist for nanoparticles (unless specifically engineered to express an export
signal – such as transferrin, as described below), and the
chances of the appropriate specific intracellular corona
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Figure 3 Schematic diagram of interaction forces acting at different stages of cellular uptake. The triangle blocks show the interaction
pathways of cellular uptake of cerium oxide nanoparticles (CNPs). CNPs with strong positive charge show better adsorption of transferrin
(Tf). The interaction between Tf and CNPs can be tuned by protonation; however, the interaction of Tf with TfR is fixed. CNPs with a strong
positive charge lead to enhanced Tf adsorption and multiple interactions with the TfRs on the cell surface. Red curved arrow inside the triangle blocks indicates the receptor mediated cellular internalization pathway of positively charged CNPs, and blue curved arrow indicates the
non-specific cellular internalization pathway of both positively and negatively charged CNPs. The red dashed circle represents the domain
of multi-point interaction between Tf:CNP and TfRs on cell surface. From [89].

arising from non-specific protein binding during uptake
are slim, [76] although potentially such signals could
arise as a result of the nanoparticles binding peptides
from the antigen processing pathways. Clearly there are
some exceptions to this general rule in the case of specialized cells such as biological barriers, where translocation is a key function, such as the air-blood tissue
barrier and the mucosal barriers where particle transcytosis, by epithelial and endothelial cells separated by
the fused basement laminae of the two cells is common
though a selective mechanism [60]. The penetration of
nanoparticles through a cell (into and out, membrane
bound) is called transcytosis or cytopempsis.
Single-walled carbon nanotubes (SWNT) were
observed to undergo exocytosis in NIH-3T3 cells, the exocytosis rate closely matching the endocytosis rate with
negligible temporal offset [91]. The exocytosis pathway
was illustrated by superimposing example particle trajectories recorded in the near infrared onto the corresponding optical image of different cells [91]. Tf, which has a
well-known recycling pathway, has been shown to induce
exocytosis of gold nanoparticles to which it is physically
adsorbed at a rate that was in linear correlation with
the nanoparticle size [92]. Fifty nm was reported as the
optimal cellular accumulation size for Tf-gold nanoparticles, due to the equilibration of the rates of uptake and
exocytosis [92].

The signalling concept: interaction
of nanoparticles with major intracellular chemical systems
The range and amount of nanoparticles humans are
exposed to is quite significant (particularly from combustion), with the increasing production of engineered
nanomaterials now contributing to this. The occupational
setting is now considered as the most likely exposure
route to engineered nanoparticles, but medical formulations may result in a wider population exposure [12]. The
contribution of exposure to ultrafine particles such as
those from combustion processes, to respiratory and skin
diseases as well as more insidious and complex pathologies such as cancer and cardiovascular dysfunction, is
now becoming apparent [93–95]. Their cumulative effects,
or more likely the knock-on effect to neighbouring cells as
well as more distant tissues and organs (i.e., paracrine signalling and cell activation) plays a key role in their toxicity
at the systemic level.
A key question to consider at the outset is whether
nanoparticles “signal” or merely perturb signalling pathways? Clearly sophisticated nanoparticles envisioned for
biomedical applications may “signal” according to their
deliberate functionalization and/or cargo of signalling
molecules/drugs/genes, but it is important to consider
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whether other, pristine or non-functionalized nanoparticles “signal”. The main thesis in the present review is
that nanoparticles can signal by virtue of their acquired
bio-corona of proteins, lipids, sugars, or other biomolecules and that studies conducted to date have not fully
taken into account the “biological” identity of nanoparticles. There are certainly some (very few) examples of
nanoparticles that appear to signal per se as a function
of their specific size, for instance, the finding that singlewalled carbon nanotubes (SWNTs) constitute a new class
of universal K+ channel inhibitors that hamper channel
function by fitting into the pore and thus either hindering
ion movement or alternatively preventing further conformational steps [96]. We believe that further studies, using
systems biology approaches, may uncover more examples
of nanoparticle-mediated signaling at doses of nanoparticles that are more realistic, and that the bio-corona and,
hence, the bio-nano-interface is likely to be an important
determinant of such signaling. This is in distinction to the
vast majority of publications to date which apply excessive amounts of nanoparticles to cells and which focus
only on crude measurements of cell death.
Mapping the research agenda for investigating nanoparticle signalling effects, the research objectives can be
broken down into three interlinked levels. Firstly, nanoparticles attached to the cell surface (cell membrane) may
trigger a cascade of signalling processes into the cell and
throughout the cell. A key question which one should ask
is whether nanoparticles need to enter a cell in order to
trigger/cause any effects inside the cell. While researchers
have long been concerned about distinguishing between
nanoparticles taken up into cells versus those adhered
to the membrane for quantification of uptake [76, 97],
less research has been directed to understanding nanoparticle-induced signalling from the cellular surface,
which is a critical knowledge gap at present although
several groups are now working on this and publications
addressing this topic will appear in the literature in the
near future [Personnal Communications from H. Hofmann
(EPFL) and K.A. Dawson (UCD)]. Secondly, nanoparticles
can signal once they are inside single cells. Here, important aspects that need to be addressed are the manner in
which nanoparticles bypass the cell membrane, enter into
the cell, localise to the mitochondria and other organelles
and finally the nucleus, causing changes in phenotypic
function and the activation of distress signals in the form
of pro-inflammatory or other molecules. The third signalling level includes the pathways by which cells communicate their response to interaction with nanoparticles to
neighbouring cells and then to more distant tissues and
organs through soluble mediators. A limited number of
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studies demonstrate paracrine signalling from nanoparticles in cells to other non-exposed cells, suggesting that
such effects may occur [98–101].
At present, much of our understanding of nanoparticle induced alterations of signal transduction is limited to
a very small space and time window. The question of how
these adaptive signals are propagated to and translated
by remote tissues and organs, how the internal milieu is
modulated by them, and the signalling pathways involved
in the translocation of nanoparticles from their point of
uptake to distant tissues have not yet been addressed.
Much of what we know of the integrative pathophysiology
of engineered nanoparticles comes from animal studies
focused on translocation and bioaccumulation [68, 102].
Translating the results to humans is not straightforward,
and as several studies on drug toxicity have shown,
caution needs to be exercised when extrapolating results
from animal models to human physiology, pathology or
toxicity [103]. Moreover, animal models are not amenable to decomposition of signalling dynamics in different tissues and organs. Additionally, given the degree of
redundancy in signalling pathways, decoupling effects of
biomolecules bound to nanoparticles from those of their
unbound counterparts will be challenging. However,
systems biology approaches are making significant strides
here [104–106].
The induction of oxidative stress is commonly viewed
as a unifying concept for understanding the cytotoxic
effects of nanoparticles, such as nano-sized metal particles and their oxides as well as those produced by combustion (including from motor vehicles) [107]. However,
it is also important to assess whether “oxidative stress”
is merely a secondary event resulting inevitably from disruption of biochemical processes and the demise of the
cell, or a specific, non-random event that plays a role in
the induction of cellular damage, e.g., apoptosis? For a
further discussion of these issues, readers are referred to
Shedova et al. [108]. The mechanism by which oxidative
damage occurs appears to be via the inhibition of electron transfer in the TCA (tricarboxylic acid) cycle and the
consequent accumulation of TCA cycle intermediates.
The TCA cycle is an essential metabolic network in all
oxidative organisms and provides precursors for anabolic
processes and reducing factors (NADH and FADH2) that
drive the generation of energy. Reactive oxygen species
(ROS) are formed in the mitochondria during respiration.
It has been shown that a healthy metabolic network plays
a key role in the defense against oxidative stress through
the production of enzymes and electron acceptors which
participate in the detoxification of ROS [109]. Interference in the mitochondrial cycle results in oxidative stress
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owing to an increase in ROS, which act as second messengers to induce a cell reaction that may eventually lead to
cell death. How nanoparticles cause oxidative stress and
subsequent apoptotic or necrotic signalling is not clearly
understood, and furthermore the process is unlikely to
be the only mechanism by which nanoparticles cause
cell and tissue damage [110]. Probing signalling mechanisms at the cellular level should focus on delving into
the mechanisms of ROS production by nanoparticles
upon entering cells, and subsequent cellular adaptation
at the nuclear level (changes in gene expression) (Figure
4). It may be worth considering whether the development of oxidative stress could be a first (unspecific) reaction mechanism to foreign material intrusion. In fact, a
short-lived reaction is compatible with a normal innate
defensive response, which resolves rapidly with limited
cell damage that is readily repaired. On the other hand,
the persistence of the reaction could lead to significant
damage from apoptosis and genotoxicity, and eventually
to cancer. Thus, understanding the origin and kinetics of
the oxidative stress induced by nanoparticles and correlating it to pathological risk could provide vital insights
in the future as to the impacts of nanomaterials. Note that
this theme of transience or duration of response is picked
up in the “kinetics concept” section, as full understanding of mechanisms will only be possible with a proper
emphasis on rate and kinetics of the various biological
processes.

A detailed investigation of the mechanism of toxicity
induced by 50 nm amine-modified polystyrene nanoparticles following uptake by 1321N1 brain astrocytoma cells
found that the nanoparticles are localized in lysosomes,
whereupon the lysosomal membrane becomes destabilized, likely because of the nanoparticle’s positive charge,
leading to release into the cytoplasm of both nanoparticles and proteolytic enzymes such as cathepsins [112].
This, in turn, results in damage to the mitochondria and
activation of caspases 3 and 7, with consequent cleavage
of PARP-1, ultimately resulting in the apoptotic death of
the cells [112]. Ongoing work has shown that the kinetics
of the lysosome membrane damage can be correlated with
the digestion of the nanoparticle protein corona in the lyso
somes which allows the underlying amine groups on the
nanoparticles to be re-exposed [113]. Smaller, fully aminated, dendritic polymer nanoparticles have been seen
to cause endosomolysis prior to transfer to lysosomes,
however, and have been seen to be later localized in the
mitochondria. In both stages, oxidative stress has been
seen to give rise to activation of caspases, inflammatory
responses and subsequent apoptotic (and other kinds of)
cell death [79, 114].
An important advance in understanding nanoparticle-induced signalling and toxicity has been achieved
utilising an integrated proteomics approach, as routinely
used to identify protein interaction pathways, to identify
the toxicity pathways and networks that are associated

Figure 4 Left: Critical aspects of intracellular signalling: mechanisms of nanoparticle (ENP) entry, ROS induction, nuclear damage and ENP
fate after cellular reaction (or death). Right: Protein interacting network 1. This representative network of differentially expressed proteins
shows the protein inter-relationships and relevant signalling pathways. Two major sub-networks within the network are centered by NF-κB
and YWHA2. Proteins in pink are up-regulated while proteins in green are down-regulated. Solid lines represent direct relationships. Dotted
lines represent indirect relationships. Lines connecting the proteins indicate known inter-relationships from the IPA database. From [111].
Whether, in this particular case the impacts can be best described as “signalling” or “perturbation of signalling” pathways is open to
debate, but the possibility that that signalling may take place at the bio-nano-interface and as such needs to be considered in the design,
and interpretation, of nanosafety and nanointeraction studies is one the main messages of the present review.
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with exposure of human bronchial epithelial cells to
nanoscale titanium dioxide [111]. Utilizing 2-DE and MS,
46 proteins that were altered at protein expression levels
were identified and mapped, using Ingenuity Pathway
Analyses™ (IPA) canonical pathways and Ingenuity
Pathway Analyses tox lists, to create protein-interacting
networks and proteomic pathways. This provided the
first preliminary protein-interacting network maps and
may give novel insights into the biological responses
and potential toxicity and detoxification pathways of
titanium dioxide [111]. However, as with many early
studies in an emerging field, there are some concerns
regarding how much can be interpreted from this study
which lacked appropriate controls [e.g., no bulk TiO2 or
other (reference) material has been used for comparison]. Another example of this approach uses proteomic
techniques including two-dimensional electrophoresis/
mass spectrometry and protein microarrays to study
the differentially expressed proteome and phosphoproteome, respectively [115]. Here, systems biology analysis
of the data revealed that unfolded protein-associated
endoplasmic reticulum (ER) stress response was the
predominant event in response to the presence of gold
nanoparticles [115].
An alternative route to inflammation, directly linked
to protein conformation and presentation at the bio-nano
interface, has recently been suggested by Deng et al. [116].
Their study demonstrated that negatively surface charged
nanoparticles can unfold fibrinogen and that the binding
of fibrinogen to poly(acrylic acid) coated gold nanoparticles of 5 nm leads to interaction with the Mac-1 receptor
and its activation, leading to a cytokine response through
degradation of IκB, subsequent release of NF-κB and its
translocation to the nucleus. Since plasmatic fibrinogen has been reported to bind many different types of
nanomaterials, including the metal oxides SiO2 and TiO2
[117], the authors proposed that fibrinogen-bound nanoparticles are potentially pro-inflammatory. Note that,
as indicated above for oxidative stress, activation of an
inflammatory pathway does not necessarily correspond to
toxicity, but is rather a defensive reaction and may cause
no overt damage if transient, and thus an understanding
of the kinetics and duration of the response to nanoparticles is vital.
An elegant approach to assessing nanoparticle
impacts has been to look at the effect of citrate-reduced
gold and silver nanoparticles on primary cultures of
murine adrenal medullary chromaffin cells [118]. Carbon-fiber microelectrode amperometry examination of
exocytosis in nanoparticle-exposed cells revealed that
nanoparticle exposure lead to decreased secretion of
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chemical messenger molecules, of up to 32.5% at 48 h of
gold nanoparticle exposure. Repeated stimulation of exocytosis demonstrated that these effects persisted during
subsequent stimulations, meaning that nanoparticles do
not interfere directly with the vesicle recycling machinery
but also that cellular function is unable to recover following vesicle content expulsion [118]. Similar results were
also observed in mast cells [118].
Beyond the level of the single cell, the means by
which injured cells communicate their distress causing
systemic and long-term damage is therefore a critical
issue. The adaptive response of nanoparticle-injured cells
is an over production of H2O2 with the consequent generation of free radicals and the secretion of pro-inflammatory cytokines [119]. Recapitulating the systemic effects of
nanomaterial toxicity in vitro requires properly scaled in
vitro and computational models so that the consequences
of localized nanoparticle induced injury to the whole
body response can be systematically investigated. Cellcell signalling, and signal propagation across the foetal
barrier has recently been shown as the toxicity mechanism by which CoCr alloy metal nanoparticles induce a
novel type of indirect genotoxic effect across cellular barriers [98, 120]. The CoCr nanoparticles were observed to
cause DNA damage and tetraploidy in cells not directly
exposed to the nanoparticles [98], i.e., on the other side
of the barrier in an in vitro model system, without a significant passage or leakage of metal through the barrier.
Such cell-cell signalling is protein mediated, and likely
triggered by something present on the nanoparticle
surface that interacts with cellular receptors, or induces
signalling from lysosomes.
It is a fair criticism of the field to date that the majority of studies published have utilised unrealistically high
doses of nanoparticles and that the “toxic effects” that
have been reported, and the assays used to detect these
effects, lack the sophistication that is needed to fully
appreciate potential nanoparticle-induced signalling
events. However, this current lack of evidence for nanoparticle-induced signalling impacts is also a consequence
of the fact that systems approaches are only beginning
to be applied to these issues, and research to address
this issue is underway. Data demonstrating nanoparticle induced signalling from nanoparticles located at cell
membranes, from nanoparticles taken up into cells, and
from nanoparticle-exposed cells to neighbouring cells will
soon begin to appear in the literature as this convergence
of nanosafety maturing as a discipline and more widespread application of systems biology approaches reaches
fruition [Personnal Communications from H. Hofmann
(EPFL) and K.A. Dawson (UCD)].
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Connecting the nature of the bio-nano interface with
downstream signalling impacts will be important in
teasing out potential longer term consequences of exposure to nanomaterials, and to correlating impacts to the
composition of the bio-nano interface and the underlying
nanoparticle physico-chemical properties.

The Kinetics concept: Timescales
of interaction of nanoparticles with
biomolecules and cells
A deep understanding of the biological effects of nanoparticles requires knowledge of the equilibrium and
kinetic binding properties of proteins (and other biomolecules such as lipids and polysaccharides) that associate with the particles, and especially under competitive
binding conditions, such as those occurring in vivo [1].
The rates by which different proteins bind to and dissociate from nanoparticles, i.e., the time scales on which
particle-associated proteins exchange with free proteins,
are critical parameters determining their interaction
with receptors, and biological responses generally. The
biological outcome may also be different, depending on
the relative exchange rates of proteins with nanoparticles and cellular receptors, respectively [3]. In addition,
the particle-bound protein may have altered exchange
rates with a cellular receptor. It is clear that, in understanding how particles will interact with cells, these
issues, currently almost unstudied, are amongst the most
fundamental. Additionally, the corona may not immediately reach equilibrium when exposed to a biological
fluid, and will evolve as the nanoparticle encounters new
milieu, for example, when particles redistribute from one
compartment or organ to another, such as upon receptormediated endocytosis from the extracellular environment
into the primary endosomal cavity, or from the cytosol to
the nucleus [44].
In addition to understanding the kinetics of formation of the corona and its evolution during nanoparticle uptake and translocation, it is vital to understand
the fate of both the nanoparticle corona and the nanoparticles themselves in their final sub-cellular locations. In particular, there is emerging evidence that
the bio-nano interface can be degraded upon localisation of the nanoparticles in endosomes or lysosomes
[113], and indeed even that some nanoparticles themselves, including carbon nanotubes, may degrade in
situ in cells or in vivo [121]. Using fluorescently labelled

proteins in the nanoparticle corona, it has been possible
to track nanoparticle localisation and corona digestion
and to correlate this with the toxicity impacts observed
[113]. Using amine-modified polystyrene nanoparticles,
a detailed event sequence has been tracked showing
how nanoparticle location and biological responses
are connected – nanoparticles are localised in the
lysosomes undergo acid-degradation of the corona,
leading to re-expression of the positive charge on the nanoparticles, which were previously masked by the presence of the protein corona, and consequently disruption
of the lysosomal wall, leading to a complex set of signalling responses [113]. For aminated dendrimers, a clear
generation dependence is observed, reflecting the systematic increase in the number of surface amino groups,
implying a similar digestion in the endosomes [79].
The ultimate goal of nanosafety assessment is to be
able to correlate the uptake rate, localisation and actual
sub-cellular dose with the kinetics of the onset and propagation of the impacts observed. This requires a good
understanding of the timing of signalling events that
various assays report on, to ensure that experiments are
designed with appropriate time-points such that desired
effects can be observed. This is especially important
for transitory or late-onset impacts, or for impacts that
are down-stream of the initial signalling impacts. Cellular responses may not be linear with dose, however,
and the process of saturation should be understood.
Equally, understanding the intrinsic cellular protection
mechanisms through antioxidants is critical to differentiating between responses of different cell types. To
fully understand the impacts of different nanomaterials,
it is important to identify the relevant cascade pathways
and to link the rates of response to the physico-chemical
properties of the nanoparticles, to their different bionano interfaces, and to the intrinsic characteristics of
the cell-lines. For all processes, the rate of response is
the most important characteristic parameter, and relevant rates include:
1. Uptake rates (endocytosis, adhesive interaction) and
connection to bio-nano interface composition
2. Impact rates of membrane bound vs. free nanoparticles
3. Signalling rate of nanoparticles attached to cell
surface – identification and quantification of most
relevant signalling markers at each time point
4. Rate of recovery of relevant signalling markers at each
time point
5. Rate of ROS generation
6. Endosomolysis thresholds and rates
7. Rates of trafficking/translocation to other organelles
(mitochondria, nuclei) and/or trancytosis
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8. Uptake rates and size thresholds for organelles
(mitochondria, nuclei)
9. Identification of impact pathways and rates (including
activation/expression of relevant signalling proteins)
10. Identification of types and kinetics of cell-cell
signalling impacts
11. Identification of kinetics of evolution [122] and
degradation of the bio-nano interface [114] and the
underlying nanoparticle degradation both prior to
uptake (i.e., in the exposure media and the influence
of media composition on nanoparticle degradation
rate for example [28]) and following uptake (for
example in the lysosomes). As recently suggested by
Shannahan et al. [123], the corona may only degrade
after lysosomal localisation (of silver nanoparticles)
resulting in acid-mediated oxidation and ultimately
cell death due to toxic metal ions. Indeed corona
degradation in the lysosomes has recently been
demonstrated utilising loss of fluorescence signal
from fluorescently-labelled serum proteins bound
to nanoparticles over time [113]. Thus, elucidating
the role of the bio-nano interface in modulating the
ionic dissolution of metal and metal-oxide based
nanoparticles is of particular importance given the
widespread role of these materials in medicine.
Coupled with this is a requirement to understand in
detail where nanoparticles are located, in order to correlate impacts with particle localisation. Significant
progress to this end has been achieved, and indeed it
is now possible to use cellular proteins associated with
the different vesicular structures of cellular uptake pathways to report on kinetics of nanoparticle uptake and
localisation. Thus, 40 nm carboxyl-modified polystyrene nanoparticles were shown to first pass through an
early endosome intermediate decorated with Rab5, but
to rapidly transfer to late endosomes and ultimately lysosomes labelled with Rab9 and Rab7, respectively [90].
Larger nanoparticles of 100 nm diameter also reach
acidic Rab9- and Rab7-positive compartments although
at a slower rate compared to the smaller 40 nm nanoparticles [90]. This information can then be coupled to the
kinetics of signalling impacts induced following localisation, and using co-localisation approaches, to qualify
particle amounts in the various compartments. Thus,
it is possible that upon entering of foreign material,
orchestrated defence processes are initiated by the cell,
depending on the nature of the nanoparticle corona, and
that concentration of nanoparticles, impact time and
reaction time would have to be considered as part of a
kinetics-based modelling approach.
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Alternative routes towards nanoparticle tracking include Raman spectroscopy. The use of Surface
Enhanced Raman Scattering from gold nanoparticles and
nanoaggregates to probe the environment of the subcellular compartments through which they are trafficked has
been demonstrated [124, 125]. This approach also demonstrated the use of molecular labelled nanoparticles as
more specific probes of the local environment [126–128].
However, the uptake rates and mechanisms as well as the
subsequent trafficking may be specific to the nanoparticle type, size and surface chemistry. More recently, Raman
spectroscopy has been employed to identify and localise
unlabelled polystyrene nanoparticles in cells in vitro [129].

What can we learn from viral
bio-nano-interfaces and their
dynamics?
Nanoparticles and virus particles share many features,
including size range. Independent of their nature, adhesion of particles in the nanometer size range depends
mainly on van der Waals forces and not on key-lock concepts as often incorrectly described [130]. Indeed, it has
been shown that adhesion processes (which are based on
van der Waals and other forces) may lead to phospholipid
molecules of the membrane moving apart to let nanoparticles enter into the cell passively [60]. Mathematically,
these van der Waals forces can be described considering
the work of adhesion, W, geometry, elasticity and forces
applied to the system. Almost four decades ago, these
forces interacting on the contact points of small particles were described by the JKR (Johnson Kendall Roberts)
analysis, F = -3πWD/8, where D is the Hertz contact diameter [131]. The measurement of these forces is possible by
applying Atomic Force Microscopy (AFM) [132]. The interparticle forces both for nanoparticles and virus particles
are very small and are in the order of thermal diffusion
forces. Measurements of self-adhesion forces leading to
doublet and triplet formation showed very similar results
for polystyrene and virus particles [133]. Proteins can
accelerate adhesion between particles/viruses and cells
and measurements of this process have revealed a stepwise process, giving evidence of several adhesive states,
with significant energy barriers between these states that
in fact allow catalytic actions to accelerate the kinetic processes leading to contact.
Theoretical models have moved from trivial and inaccurate lock-and-key-models to the more physically relevant
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van der Waals principles. On the scale of such models,
Brownian motion cannot be neglected and thereby adhesion becomes a statistical process leading to a dynamic
equilibrium that depends on concentration, thermal
energy and the attractive potential. Further research into
adhesion and molecular dynamics modelling will allow
improved visualization and understanding of the molecular basis of adhesion processes. A recently presented
experimental procedure showed that nanoparticles can
be functionalized with appropriate ligands to render them
membrane-permeant [80]. Recent characterization of the
trafficking mechanisms of prion proteins and certain bacteria may present new paradigms for understanding how
nanoparticles could enter cells [60, 134].

Nanoparticle interactomes:
emerging systems biology
approaches in nanotoxicology
Systems biology is an emerging field which seeks to integrate high-throughput biological studies to understand
how biological systems function [135, 136]. By studying the
relationships and interactions between various parts of a
biological system (e.g., metabolic pathways, organelles,
cells, physiological systems, organisms, etc.) it is hoped
that eventually an understandable model of the whole
system can be developed. One successful approach has
been to determine protein interactomes, which are maps
or networks connecting a protein to all the other proteins
with which it interacts directly or indirectly [137, 138].
This is possible for proteins, as they must interact with
other molecules in order to fulfil their biological roles. For
instance, enzymes, receptors, and transcription factors
have to bind their substrates, ligands, and target DNA
elements, respectively, to execute their function. Thus,
removal of one protein will affect the functioning of other
proteins, which will in turn affect the functioning of other
proteins in a complex network functioning.
Small changes in a protein conformation, such as may
be induced by interaction with the surface of a nanoparticle (both engineered and combustion derived) [21], can
potentially have large impacts on a protein’s function,
as well as its interaction with other proteins and in this
way affect their function. Thus, introduction of nanoparticles into living systems can affect a whole series of interrelated processes, simply by altering the behaviour of one
or two key proteins, which in turn affects the protein-protein interactions. This sort of network type behaviour is

referred to as a protein’s interactome, and an example of
such a connectivity diagram for a nanoparticle-induced
toxicity pathway is shown in Figure 4. Thus, a key challenge for the future is to identify the protein networks that
are affected by introduction of different nanoparticles,
and in this way to determine the nanoparticles’ interactome, and connect this to the nature of the nanoparticles’
bio-nano interface.

Towards predicting n
 anoparticle fate
and behavior in living organisms
based on the bio-nano interface
If the bio-nano interface is what is actually seen by, and
interacts with, organisms, then in principle, mapping
and reading a large number of nanoparticle bio-nano
interfaces could provide a mechanism for grouping and
classification of nanomaterials, and indeed even for predicting nanoparticle fate and behaviour in the future
based on the initial bio-nano interface at the point of
first contact with a biological system. There is a need for
advanced methodologies to study nanoparticles in situ in
biofluids, and to understand the packing rules and orientational drivers for specific proteins and other biomolecules to locate at the bio-nano interface, and from this
to understand nanoparticle interactomes, or networks
of signalling molecules that can be triggered by different
bio-nano interfaces.
It is clear that the final cellular location of a nanoparticle will determine the range of cellular pathways and processes that the particle can potentially trigger or disrupt,
and thus reaching different intracellular locations leads to
different potential functional responses. Once the nanoparticle characteristics can be connected to the nature of
the biomolecule layer adsorbed onto the particle, i.e., the
bio-nano interface, and the details of the surface exposed
peptides or amino acid groups available for interaction
with endogenous machinery and other biomolecules, the
details of the bio-nano interface can be correlated to the
biological responses resulting from the presence of the
nanoparticle in vivo.
However, characterising the nature of the nanoparticle corona and the bio-nano-interface is not a trivial
task. The recent review by Saptarshi et al. [140] provides
a table summarising the approaches that have been utilised in the recent literature to study nanoparticle-protein
interactions, with a focus on methods to assess nanoparticle surface driven protein conformational changes and
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uptake of nanoparticles by cellular structures. An earlier
review included a more diverse set of approaches, including ones routinely used for assessment of protein-protein
interactions, including NMR, phage display libraries,
limited proteolysis and many others [141]. An elegant
paper by Cukalevski et al. demonstrates that nanoparticle
surface charge is a critical parameter for predicting structural changes in adsorbed proteins, as circular dichroism,
fluorescence spectroscopy, and limited proteolysis experiments indicated effects on both secondary and tertiary
structures, with the effect being specific for each protein
studied [21]. Use of advanced imaging approaches such as
Raman microscopy can provide important insights regarding the impact of a bio-corona (e.g., using surface-grafted
adenosine triphosphate (ATP) as a model of a corona
formed in alveolar liquid) on nanoparticle uptake and
the fate of the nanoparticles and the protein corona [142].
Raman microscopy unambiguously showed that magnetite nanoparticles are internalized within A549 cells after
24 h co-incubation, and that the ATP ligand is retained
on the nanoparticles throughout the uptake process [142].
Other important approaches include Fluorescence Correlation Microscopy which can be used to study the protein
organisation in the corona such as the number of proteins,
and whether a monolayer or multi-layer forms and even
provides information about the residence time of proteins
(although at present limited to single proteins studies)
[143], and of course the recent advances in proteomics
approaches (e.g., label-free snapshot proteomics) applied
to nanoparticles allow quantitative and time-resolved
assessments of amount and composition of proteins in
nanoparticle coronas [144]. While significant progress is
being made, the experimental approaches employed by
many studies currently involve detailed study of a single
protein with the nanoparticle surface rather than the
complete biofluids studies where significant competitive
and cooperative binding effects come into play. Additional method development, or optimisation of methods
to address and fully characterise dynamic nanoparticle
bio-nano-interfaces is required.
Given that it is the nature of the adsorbed protein
coating that determines uptake and intracellular trafficking of nanoparticles, in principle, one can begin to think
of designing nanoparticles to adsorb specific proteins in
order to determine the final cellular location of the nanoparticles. In principle, we should be able to “post” a nanoparticle to anywhere in the cell, simply using the bio-nano
interface which will be “read” by the cellular machinery,
and direct the nanoparticle to the desired location according to the instructions “printed” on the nanoparticle
surface, via the bio-nano interface. By understanding
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the nature of the bio-nano interface that leads to localisation in specific intracellular locations, versus recycling
out of cells, tissues or organs, it may be possible to design
nanoparticles that acquire such coatings spontaneously,
leading to nanomaterials that are safe by design [145] of
their bio-nano interface.

Bio-nano interface based structureactivity relationships?
Nanoparticle uptake, intracellular trafficking and cellular response mechanisms have been extensively studied
in vitro. Although the extent to which results of in vitro
models are translatable to in vivo exposures is debateable, such models potentially provide a basis for rapid
screening of potential toxicants or nanobased medical
treatments and also provide an insight into cellular
interactions of nanoparticles. Furthermore, Directive
2010/6386/609/EU on the protection of animals used for
experimental and other scientific purposes indicates
that the EU Commission and the member states should
actively support the development, validation and acceptance of methods which could reduce, refine or replace
the use of laboratory animals (3Rs). However, given the
myriad of nanoparticle types, each potentially with variable chemical functionalisations and sizes, and each of
which can present a different bio-nano interface depending on the exposure conditions (media pH, ionic strength,
biomolecule composition, etc.), and given the similarly
huge number of cell types and lines, purported to represent target organs in vivo, the route towards Quantitative
Structure Activity Relationships (QSARs) is not clear. In
toxicology, responses are commonly classified in terms
of effective concentrations which elicit an endpoint of an
in vitro or in vivo assay, but, for a given nanoparticle, significant variations can be seen between different assays
and cell lines. It is therefore important to identify critical
points and rates of interaction between nanomaterials
and biological signalling pathways, most notably via the
bio-nano interface, and identify routes towards establishing quantifiable parameters governing the activity of
nanoparticles and their structural dependences. A novel
biological surface adsorption index (BSAI) for nanoparticles that was proposed for use to predict the “biological
identity” of nanoparticles (see Figure 5) could serve as a
useful descriptor in modelling of nanoparticle structureactivity relationships [139]. Notably, consideration should
be given to both acute and chronic effects, and indeed to
the potential for novel other end-points (not yet identified
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Nanoparticle adsorption sites
Small molecules

Nanoparticle
core

Solid-liquid interface

Corona-media
interface

Amino-acid residues
Nanoparticles

Small molecules

Plasma proteins

Figure 5 Illustration of the competitive adsorption of small molecules and proteins onto the surface adsorption sites of nanoparticles. Left:
in a physiological environment, nanoparticles are exposed to different proteins and small molecules. Right: the competitive adsorption of
small molecules (upper) and the amino-acid residues of proteins (lower) on a nanoparticle. The orange ring on the nanoparticle with blue
irregular shapes represents the adsorption sites that are not uniformly distributed on the nanoparticle surface. Small molecules with known
molecular descriptors [R, π, α, β, V] can be used as probes to measure the molecular interaction strengths of the nanoparticles with small
molecules and biomolecules. From reference [139]. Note that the particles, small molecules and proteins are not drawn to scale.

within the scope of OECD2 or other approaches), such
as the influence of nanoparticles on protein fibrillation
in situ, and the frustrated phagocytosis caused by high
aspect ratio nanomaterials such, as carbon nanotubes,
identified in the SCENIHR Opinion on Risk Assessment
of Products of Nanotechnologies [146]. Indeed, it is worth
reiterating that even now there is no simple toxicity assay
or combination of assays that could predict mesothelioma, the asbestos-induced cancer [147].

Conclusions and recommendations
for researchers
This review paper has described some of the key research
towards understanding the role of the layer of adsorbed
biomolecules (the biomolecule corona) on the fate and
behaviour of nanoparticles upon contact with living
systems. We have focussed the existing data and knowledge
around four key concepts to demonstrate the central role of
2 Organisation for Economic Cooperation and Development.

the bio-nano interface for understanding, and eventually
predicting, nanoparticle interactions, impact and safety.
These four concepts are: Coating, Translocation, Signalling
and Kinetics. As demonstrated by the degree of cross-referencing between the concepts, each is closely linked with
the others and can only be fully understood in light of the
others. Based on the above discussions, a number of key recommendations for researchers have been drawn, to help in
the framing of future experimental approaches, as follows:
1. Recognise that nanoparticles cannot be treated
(regulated) as non-interacting species, but rather
must be thought of, and studied as, biological entities,
which interact with proteins and other molecules
in the (micro)environment and are influenced by
this biomolecule interface in all their subsequent
interactions with organs, tissues cells, intracellular
organelles. Thus, the key parameter to understand
nanoparticle interactions with living systems and their
biological impacts, becomes the nature, composition,
organisation and structure, and evolution of the bionano interface [42], which is a consequence of their
physico-chemical parameters and the nature of the
biological microenvironment [54].
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2.

In its simplest manifestation, this then suggests
that studies of nanoparticle interactions with living
systems should include as standard characterisation
of the nanomaterials size, size distribution, surface
charge as a minimum in the dispersion medium in
which they will be exposed to the test species. Some
visualisation of the agglomeration state should also
be included where possible, such as Electron Micro
scopy imaging coupled with, for example, Differential Centrifugation Sedimentation, which reports
on the distribution of particle monomers, dimers,
trimers and larger aggregates in complex biofluids
[5]. Research Infrastructures such as FP7-QualityNano
(www.qualitynano.eu) are an important mechanism to provide access to such methodologies to the
nanosafety research community.
A more advanced manifestation of this requires the
development of new tools and approaches to characterise the bio-nano interface in detail, including mapping
the outermost peptide sequences of the proteins contained in the nanoparticle-corona, as it is these amino
acid sequences that will be available to engage with
biological machinery. Depending on the orientation
of proteins in the corona, and their degree of unfolding, new or so-called “cryptic” presentations of amino
acids could result from protein binding to nanoparticles, resulting in the potential for new protein-protein
interactions and/or altered signalling [140, 141, 148].
Recognise the central role of the bio-nano interface as
the determinator of nanoparticle fate and behaviour
in the environment and in humans, and frame studies
in a manner that connects uptake and impacts to bionano interface and its signalling interactome, i.e.,
the full set of other biomolecules that interact with
the biomolecules at the bio-nano interface and the
signalling implications of these.
This also requires a reassessment of how we design in
vitro experiments to be representative of in vivo conditions, and to allow in vitro-in vivo correlations, taking
account of the fact that quite different bio-nano interfaces can result from different mass transport, kinetic
and concentration regimes. Thus, the 3–10% serum
and stationary (steady-state) conditions typical of in
vitro experiments may not be fully suitable to predict
the bio-nano interface and the consequent impacts
from the same nanomaterials subject to interstitial or

3.
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vascular flow rates and protein concentrations typical
in vivo (55–80% protein).
Consider a framework for classification of
nanomaterials based on the details of their bio-nano
interface and its stability, evolution and degradation
rather than one based solely on underlying physicochemical properties. In this way, direct connections can
be made with potential for bioaccumulation, potential
for degradation, and other more direct toxicities in
addition to allowing more subtle effects from perturbed
signalling pathways to emerge. It will also enable
issues such as opsonisation and immunogenicity, and
the potential for nanomaterials to modulate protein
fibrillation to be addressed as part of the assessment
process. Important steps here will include a detailed
understanding of the conditions under which
nanoparticle exocytosis may occur, and how signals
for exocytosis could be “designed” into the bio-nano
interface, in first steps towards safety by design.
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